Prothrombin fragments F1+2, thrombin-antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis

International Journal of Cardiology

Volumn 68, Issue 3, 1999, Pages 269-274

  Giannitsis, Evangelos ^a   Siemens, Hans J ^a   Mitusch, Rolf ^a   Tettenborn, Ivo ^a   Wiegand, Uwe ^a   Schmücker, Georg ^a   Sheikhzadeh, Abdolhamid ^a   Stierle, Ulrich ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Coronary artery disease; D Dimer; Fibrin monomer; Fibrinogen; Prothrombin fragments; Thrombin antithrombin III complex

Indexed keywords

ANTITHROMBIN III; PROTHROMBIN; THROMBIN;

ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; FIBRIN FORMATION; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0033559725     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(98)00256-3     Document Type: Article

References (29)

1. Meade T.W., Mellows S., Brozovic M., Miller G.J., Chakrabarty R.R., North W.R.S., Haines A.P., Stirling Y., Imeson J.D., Thompson S.G. Haemostatic function and ischemic heart disease: principal results of the Northwick Park heart study. Lancet. 2:1986;533-537.
2. Thompson S.G., Kienast J., Pyke S.D.M., Haverkate F., Van de Loo J.C.W. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New Engl J Med. 332:1995;635-641.
3. Wilhelmsen L., Svärdsudd K., Korsan-Bengtsen K., Larson B., Welin L., Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. New Engl J Med. 311:1984;501-555.
4. Rosengarn A., Wilhelmsen L., Welin L., Tsipogianni A., Teger-Nilsson A.C., Wedel H. Social influences and cardiovascular risk factors as determinants of plasma fibrinogen concentration in a general population sample of middle aged men. Br Med J. 300:1990;634-638.
5. Small M., Lowe G.D.O., Douglas J.T., Hutton I., Lorimer A.R., Forbes C.D. Thrombin and plasmin activity in coronary artery disease. Br Heart J. 60:1988;201-203.
6. Van Hulsteijn H., Kolff J., Briet E., Van der Laarse A., Bertina R. Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction. Am Heart J. 107:1984;39-45.
7. Uno M., Tsuji H., Watanabe M., Takada O., Kobayashi K., Toyoda T., Yamamoto K., Katoh K., Nakagawa M. Application of thrombin-antithrombin III complex for detecting a latent hypercoagulable state in patients with coronary artery disease. Jpn Circ J. 53:1989;1185-1191.
8. Hamsten A., Blombäck M., Wiman B., Svensson J., Szamosi A., deFaire U., Mettinger L. Haemostatic function in myocardial infarction. Br Heart J. 55:1986;58-66.
9. Gallino A., Haeberli A., Baur H.R., Straub P.W. Fibrin formation and platelet aggregation in patients with severe coronary artery disease: relationship with the degree of myocardial ischemia. Circulation. 72:1985;27-30.
10. Sobel M., Salzman E.W., Davies G.C.et al. Circulating platelet products in unstable angina pectoris. Circulation. 63:1981;300-306.
11. ECAT Angina Pectoris Study Group. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993;14:8-17.
12. Kienast J., Thompson S.G., Raskino S., Pelzer H., Fechtrup C., Osterman H., van de Loo J. Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. Thromb Haemost. 70:1993;550-553.
13. Ho C.H., Wang S.P., Jap T.S. Hemostatic risk of coronary artery disease in the Chinese. Int J Cardiol. 51:1995;79-84.
14. Bauer K., Rosenberg R.D. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood. 70:1987;343-349.
15. De Wood M.A., Spores J., Notsuke R., Mouser L.T., Burrough R., Golden M.S., Lang H.T. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. New Engl J Med. 303:1980;897-902.
16. Pelzer H., Schwarz A., Heimburger N. Determination of human thrombin-antithrombin-III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost. 59:1988;101-106.
17. Pelzer H., Schwarz A., Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost. 65:1991;153-159.
18. Schmitz-Huebner U., Thompson S.G., Balleisen L., Fechtrup C., Grosse-Heitmeyer W., Kirchhof B., Most E., Müller U.S., Seifert C., Seiffert D., van de Loo J. Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis. Br Heart J. 59:1988;287-291.
19. Nichols A.B., Owen J., Kaplan K.L., Sciacca R.R., Cannon P.J., Nossel H.L. Fibrinopeptide A, platelet factor 4, and beta-thromboglobulin levels in coronary artery disease. Blood. 60:1982;650-654.
20. White G.C., Marouf A.A. Platelet factor 4 levels in patients with coronary artery disease. J Lab Clin Med. 64:1981;626-632.
21. Levine S.P., Lindenfeld J., Ellis J.B., Raymond N.M., Krentz L.S. Increased plasma concentrations of platelet factor 4 in coronary artery disease. Circulation. 64:1981;626-632.
22. Suzuki T., Yamauchi K., Matsushita T., Furumichi T., Furui H., Tsuzuki J., Saito H. Elevation of factor VII activity and mass in coronary artery disease of varying severity. Clin Cardiol. 14:1991;731-736.
23. Yamauchi K., Suzuki T., Furumichi T., Saito H. Plasma t-PA/PAI-1 complex and blood coagulability in patients with coronary artery disease. Jpn Heart J. 33:1992;351-359.
24. Görög P, Ridler CD, Rees GM, Kovacs. Evidence against hypercoagulability in coronary artery disease. Thromb Res 1995;79:377-85.
25. Fuster V, Badimon L, Badimon J, Chesebro JH. Review article: the pathogenesis of coronary artery disease and the acute coronary syndromes. New Engl J Med 1992;228:242-50 and 310-8.
26. Angleton P., Chandler W.L., Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation. 79:1989;101-107.
27. Andreotti F, Lefroy DC, Offeringa L, Crake T, Maseri A, Kluft C. and the BEST Investigators. Activation of coagulation and fibrinolysis in acute or chronic coronary artery disease. Fibrinolysis 1994;8(Suppl 2):122-3.
28. Falciani M., Gori A.M., Fedi S., Chiarugi L., Simonetti I., Dabizzi R.P., Prisco D., Pepe G., Abbate R., Gensini G.F., Neri Serneri G.G. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost. 79:1998;495-499.
29. Ulutin T., Sonmez H., Ucisik N., Suer S., Bayram C., Kokoglu E., Sultuybek G. The molecular markers of hemostatic activation on coronary artery disease. Thromb Res. 88:1997;329-332.